Eli Lilly and Company $LLY Shares Purchased by Evoke Wealth LLC

Key Points

• Evoke Wealth LLC boosted its Eli Lilly stake by 9.5% in the fourth quarter, bringing its holdings to 11,220 shares worth about $12.1 million.
• Wall Street sentiment remains bullish, with Goldman Sachs and Jefferies both raising price targets on LLY to $1,283 and $1,330, respectively, while the consensus rating stays at Moderate Buy.
• Eli Lilly posted a strong quarter, reporting $8.55 EPS and $19.8 billion in revenue, both above estimates, with revenue up 55.5% year over year; the company also announced a quarterly dividend of $1.73 per share.

Evoke Wealth LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 9.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,220 shares of the company's stock after purchasing an additional 972 shares during the period. Evoke Wealth LLC's holdings in Eli Lilly and Company were worth $12,058,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Principle Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 86.3% during the 4th quarter. Principle Wealth Partners LLC now owns 12,674 shares of the company's stock worth $13,620,000 after purchasing an additional 5,872 shares during the last quarter. Gradient Capital Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $256,000. Keudell Morrison Wealth Management acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $5,534,000. Wilian Securities LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $704,000. Finally, Prospect Financial Services LLC raised its holdings in Eli Lilly and Company by 6.7% in the 4th quarter. Prospect Financial Services LLC now owns 1,356 shares of the company's stock valued at $1,457,000 after acquiring an additional 85 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Analysts Set New Price Targets

LLY has been the subject of a number of recent research reports. Scotiabank reiterated an "outperform" rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Argus increased their price objective on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a "buy" rating in a report on Monday, February 9th. Leerink Partners cut their price objective on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating for the company in a report on Monday, April 27th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 2nd. Finally, Sanford C. Bernstein reiterated an "outperform" rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,220.37.

Eli Lilly and Company Stock Up 2.4%

Shares of NYSE LLY opened at $1,066.59 on Friday. The company has a 50 day simple moving average of $942.87 and a 200-day simple moving average of $1,003.77. The company has a market capitalization of $1.00 trillion, a P/E ratio of 37.89, a P/E/G ratio of 1.13 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business's revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.